Synonyms: Flotros® | IP-631 | IP631 | Regurin® | Sanctura®
trospium is an approved drug (FDA (2004))
Compound class:
Synthetic organic
Comment: The marketed product contains trospium chloride (PubChem CID 107979). Note that the INN record for trospium chloride represents a chiral molecule, the closest PubChem match being AC1NR4SW. Our representation and those contained in our links show the non-isomeric molecule.
Trospium is a peripherally restricted muscarinic receptor antagonist. |
|
References |
1. Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, Miller AC, Paul SM, Brannan SK. (2024)
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet, 403 (10422): 160-170. [PMID:38104575] |
2. Pak RW, Petrou SP, Staskin DR. (2003)
Trospium chloride: a quaternary amine with unique pharmacologic properties. Curr Urol Rep, 4 (6): 436-40. [PMID:14622495] |
3. Sauder C, Allen LA, Baker E, Miller AC, Paul SM, Brannan SK. (2022)
Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study. Transl Psychiatry, 12 (1): 491. [PMID:36414626] |